An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma

Size: px

Start display at page:

Download "An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma"

Elaine Hampton
5 years ago
Views:

1 This list covers the Principal Treatment Centre (Alder Hey) and POSCUs including community services. It covers solid tumour oncology and haemato-oncology clinical management protocols and agreed chemotherapy protocols/regimens and specifies those that are deliverable in the community. (). List is correct March 2017 More detailed regimen specific information is available from, R & D Alder Hey approved Trust protocols and the Alder Hey PTC Trial Protocols Bone Diagnosis Trial Oral Chemo Protocol Title Ewing sarcoma Euro Ewing 2012 International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours Relapsed/refractory Ewing reecur Temozolomide International Randomised Controlled Trial of Chemotherapy for the Treatment sarcoma of Recurrent and Primary Refractory Ewing Sarcoma POSCU Involvement Supportive Care Level 1 G-CSF administration? G-CSF administration? Referral to Outside CCN Surgery at Royal Orthopaediac Hospital Birmingham / Closed to Recruitment CNS Low Grade Glioma LGG 2 Cooperative Multicentre Study for Children And Adolescents With Low Grade Glioma Intracranial Germ Cell SIOP CNS GCT II, Prospective trial for the diagnosis and treatment of children, adolescents and Tumour young adults with Intracranial Germ Cell Tumour. Standard Risk Medulloblastoma Ependymoma PNET 5 Lomustine AN INTERNATIONAL PROSPECTIVE STUDY ON CLINICALLY STANDARD-RISK MEDULLOBLASTOMA IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH LOW-RISK BIOLOGICAL PROFILE (PNET 5 MB - LR) OR AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR) SIOP Ependymoma II An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma G-CSF administration at discretion of prescriber HODGKINS dular lymphocytepredominant Hodgkin s LEUKAEMIA Acute Lymphoblastic Leukaemia (ALL) and lymphoma EuroNet-PHL-LP1 Prednisolone UKALL 2011 Mercaptopurine, Methotrexate, Infant ALL Interfant 06 Methotrexate, Tioguanine, Mercaptopurine, Busulfan, Acute Meyloid Leukaemia Myechild01 EuroNet-Paediatric Hodgkin s Group. First international Inter-Group Study for nodular lymphocyte-predominant Hodgkin s in Children and Adolescents United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and 2011 Cytarabine administration Interfant-06 Cytarabine administration International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia incorporating an embedded dose finding study for gemtuzumab ozogamicin (GO )in combination with induction chemotherapy NEUROBLASTOMA High Risk Neuroblastoma HRNBL Isotretinoin High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) G-CSF administration Relapsed / Refractory Neuroblastoma GD2 Isotretinoin Long term continuous infusion ch14.18/cho plus s.c. aldesleukin (IL-2)

2 B-CELL NHL OR B-AL: HIGH RISK PATIENTS Relapsed/refractory Mature B-Cell NHL SOFT TISSUE SARCOMA n-rhabdomyosarcoma Soft Tissue Sarcoma / Malignant Rhabdoid Tumour n Metastatic Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Relapsed / Refractory Rhabdomyosarcoma Protocol Inter-B- NHL ritux 2010 Prednisolone INTERGROUP TRIAL FOR CHILDREN OR ADOLESCENTS WITH B-CELL NHL OR B-AL: EVALUATION OF RITUXIMAB EFFICACY AND SAFETY IN HIGH RISK PATIENTS Sparkle Ibrutinib Ibrutinib Ph.3 Study in paediatric patients relapsed/refractory Mature B-Cell non-hodgkin with PK run in portion NRSTS 2005 STS EpSSG NRSTS 2005 A protocol for n-rhabdomyosarcoma Soft Tissue Sarcomas no G-CSF administration RMS 2005 Cyclophosphamide RMS 2005 A protocol for n Metastatic Rhabdomyosarcoma G-CSF administration at STS discretion of prescriber RMS 2005 Information in RMS 2005 A protocol for n Metastatic Rhabdomyosarcoma. G-CSF administration at STS Phase III discretion of prescriber VIT 0910 Temozolomide International Randomized Phase II Trial of the Combination of Vincristine and Irinotecan with or without Temozolomide (VI or VIT) in Children and Adults with Refractory or Relapsed Rhabdomyosarcoma

3 Clinical Management Protocols Incorporating the Agreed List of Chemotherapy Regimens (continued) n Trial Protocols Diagnosis Regimen Oral Chemo POSCU Involvement Supportive Care Level 1 Referral to Outside CCN Approval Method BONE Relapsed / Refractory Ewings Irinotecan / Temozolomide Temozolomide Approved CDEG Osteosarcoma, localised Guidelines - Standard Chemotherapy Osteosarcoma plus mifamurtide mifamurtide Recommendation to Use Closed Euramos Protocol administration Metastatic Osteosarcoma Guidelines - Standard Chemotherapy Osteosarcoma CDEG Approved Relapsed Osteosarcoma Ifosfamide & etoposide (as per EURAMOS) GCSF administration CDEG APPROVED CNS Atypical Teratoid Rhabdoid Tumour (ATRT) Guidelines for Management of ATRT advise EURHAB Protocol Guidelines advise EURHAB closed trial Low Grade Glioma LGG 2 Cooperative Multicentre Study for Children And Adolescents With Low Grade Glioma Closed trial High Grade Glioma High Grade Glioma Guidelines (12MONTHS TEMOZOLOMIDE) Temozolomide Relapsed/refractory High Grade Glioma PCV (Lomustine,Procarbazine and Vincristine Lomustine, Procarbazine Historical approved at chemo group approval Recurrent high grade glioma Carmustine wafers CDEG May Funding agreed alert pharmacist NWest Hub (helenpotter1@nhs.net). IFR Wales,IOM Infant High Grade Glioma HIT-HGG International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine Proposed trial as guidelines. ITC/Intraventricular chemoherapy at consulatnts discretion glioma, and gliomatosis cerebri in children and adolescents < 18 years. Trial not open - draft. Refractory Low Grade Glioma Bevacizumab and Irinotecan CDEG Approved. Funding via CDF. Welsh patients IFR WHSCC,IOM Refractory Low Grade Glioma vinblastine weekly Historical High Risk Medulloblastoma M1-M4 >3Yrs Use ST Jude s MB03 with risk adapted standard craniospinal RT post surgery Recommendation. and 4 courses of HD cyclophosphamide/cisplatin. High Risk Medulloblastoma M1-M4 >3Yrs POG 9031 Cisplatin Etoposide Recommendation. n-meta Medulloblastoma M0 >3yrs Standard Risk Medulloblastoma Guideline Lomustine Medulloblastoma < 3 yrs M+ OR R+ Headstart II - modified. Includes infants with non-desmoplastic phenotype Temozolomide, Etoposide GCSF administration on morphology Relapsed Medulloblastoma / PNET guidelines includes treatment detailed in closed trial CNS Supratentorial PNET <3yrs (including infants with Headstart II - modified Temozolomide, Etoposide GCSF administration non-desmoplastic phenotype on morphology) CDEG Infant Medulloblastoma Proposed Infant Medulloblastoma - based on SIOP YC MB proposal, Paris 2014 Temozolamide CDEG closed trial

4 Recurrent/progressive medulloblastoma MEMMAT - metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma Thalidomide Etoposide Cyclophosphamide CDEG March t funded - require IFR. IFR Wales,IOM Ependymoma < 3 yrs UKCCSG Infant Ependymoma Interim Guidelines Version 1 May 2006 Ependymoma > 3 yrs guidelines (Ependymoma 99) Relapsed Ependymoma Closed trial Phase II Study of Intravenous Etoposide in Patients with Relapsed Ependymoma (CNS ) Closed trial Recurrent ependymoma Carmustine wafers CDEG May t funded - require IFR. IFR Wales,IOM n-metastatic Pineoblastoma > 3YEARS New guidelines n-metastatic Pineoblastoma in Children more than 3 years Sep 2013 Choroid Plexus Tumours CNS SIG v cycles of CarbEV:Carboplatin,Vincristine, Etoposide v 2015,. Palliative brain tumour chemotherapy Oral temozolomide Temozolomide Published Protocol Palliative brain tumour chemotherapy Oral Etoposide Etoposide NAG 8 - Historical Protocol High Risk, unresponsive, progressive or relapsed High dose carboplatin and thiotepa +/- etoposide with stem cell rescue malignant brain tumours in patients up to 19 years CDEG Approved July 2012 GERM CELL Extra-cranial Germ Cell tumours Interim Guidelines for the Treatment of Extracranial Germ Cell Tumours Resistant Germ cell Oxaliplatin & Gemcitabine HISTIOCYTOSIS HLH HLH 2004 Protocol, Ciclosporin Historical Protocol (Trial Closed) LCH Guidelines - Langerhans Cell Histiocytosis Mercaptopurine, Prednisolone Relapsed / Resistant LCH LCH-S-2005 Protocol - Cladrabine +/- Cytarabine Mercaptopurine, Methotrexate Historical Protocol (Trial Closed) LCH progression HODGKINS Classical Hodgkin`s Treatment based on Stratum 2 of the upcoming trial protocol LCH IV (Vincristine, Prednisolone,cytarabine) EuroNet-Paediatric Hodgkin s Group. Recommendations for the Diagnostics and Treatment of children and adolescents with a classical Hodgkin`s during the Interim phase between the end of the EuroNet-PHL-C1 Study and the start of the EuroNet-PHL-C2 Study Prednisolone Prednisolone new as per guideline Relapsed / Refractory Hodgkins Brentuximab CDEG Approved. Funding via CDF, Welsh patients IFR (OFF Euronet PHL-C1) WHSCC/IOM IGEV chemotherapy (Ifosfamide, Gemcitabine, Vinorelbine, prednisolone) Prednisolone Relapsed Hodgkins's First International Inter-Group Study for classical Hodgkin's lymphoma in Closed trial. Use for Beam dosing only Relapsed Hodgkins's Children & Adolescents (EuroNet-PHL-C1): BEAM only Classical Hodgkin`s -alternative Tx ABVD - doses as per MCCN protocol LEUKAEMIA ALL Interim Guidelines for the Treatment of CYA with ALL and LBL cytarabine administration Relapsed ALL An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL) - follow standard arm Methotrexate, Tioguanine, Mercaptopurine, Advice

5 Relapsed/Refractory ALL FLA(+/- G) or FLA - IDA Historical Relapsed/Refractory ALL Clofarabine with cyclophosphamide, etoposide, Peg aspasaginase and CDEG Approved. Funding via CDF or check WALES/IOM dexamethasone (see closed R3) as a bridge to transplant Relapsed/Refractory T cell ALL Guidelines based on Nectar 2015 : Nelarabine and modified R3 therapy. Nelarabine funded on CDF or Check WALES/IOM Philadelphia Positive ALL Interim Recommendations for Ph+ ALL in Children - utilising closed trial EsPhALL Imatinib, Methotrexate, Mercaptopurine, cytarabine administration UK Guidance. DASATINIB may be used if imatinib not tolerated - not funded needs IFR. Chronic Myeloid Leukaemia Guidelines for the Management of Chronic Myeloid Leukaemia in Children Imatinib UK Childhood Leukaemia Working Party Acute Promyeloctic Leukaemia APL Protocol UK V1 Management Guidelines ATRA, Methotrexate, Mercaptopurine Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome Acute Myeloid Leukaemia in Down's Syndrome Treatment Guidelines for AML or High Risk Myelodysplastic Syndrome Jan 2016 ML-DS 2007 A Treatment Recommendation for Acute Myeloid Leukaemia of Down syndrome for adoption by the Children s Cancer and Leukaemia Group () and the United Kingdom and Republic Of Ireland Childhood Leukaemia Clinicians Network Leukaemia Subgroup NCRI Children s Cancer and Leukaemia Clinical Studies Group WEBSITE Guideline Chronic Myeloproliferative Disorders Treatment Recommendations for Chronic Myeloproliferative Disorders in Aspirin, Hydroxycarbamide, UK Childhood Leukaemia Working Party Childhood Anegrilide Relapsed AML Relapsed non APL AML 2010 Historical. Daunoxome requires IFR. Relapsed/Refractory AML FLA(+/- G) or FLA - IDA Historical Relapsed/Refractory AML Clofarabine with chemotherapy as a bridge to transplant CDEG Approved. Funding via CDF or WHSCC JMML Leukaemias with ABL Translocations in Patients with Imatinib RESISTANCE OR INTOLERANCE APLASTIC ANAEMIA Mercaptopurine, IV cytarabine, ITC (cytarabine, hydrocortisone), Mercaptopurine progressing to AML type treatment and BMT if required. Dasatinib Dasatinib CDEG Approved Relapsed/Refractory ALL. IFR required. Aplastic Anaemia in Childhood Treatment Aplastic Anaemia in Childhood Treatment Recommendations Version 3.1 4th July 2013 LIVER Hepatoblastoma ( Standard risk, High Risk, metastatic and recurrent) NEUROBLASTOMA Treatment guidelines for hepatoblastoma (including recurrent disease) August 2015 (finalised June 2016) Relapsed/Progressive High Risk Neuroblastoma NEUROBLASTOMA SPECIAL INTEREST GROUP Options for the Treatment of Patients with Relapsed/Progressive High Risk Neuroblastoma March 15 Relapsed Neuroblastoma In-house metronomic chemotherapy Cis-retinoic acid, etoposide, celecoxib, temozolomide, Imatinib solid tumour

6 Low and Intermediate Risk Neuroblastoma Burkitt/Burkitt like and B large cell n-hodgkin T-cell and B cell lymphoblastic lymphoma Relapsed n Hodgkins Guidelines Treatment of Patients with Low/Intermediate Risk Neuroblastoma Jan 2015 Interim Guidelines for the Management of Burkitt/Burkitt like and B large cell n-hodgkin Prednisolone Interim Guidelines for treatment of Children and Young Persons with Acute Prednisolone, dexamethasone, Cytarabine administration Lymphoblastic Leukaemia and Lymphoblastic mercaptopurine IGEV (+/- Rituximab) chemotherapy for relapsed non hodgkins lymphoma Prednisolone, September 2016 (Ifosfamide, Gemcitabine, Vinorelbine and prednisolone) Anaplastic Large Cell Guidelines Recommending ALCL 99 Relapsed Anaplastic Large Cell NHL ALCL Relapse Protocol Closed Trial Lomustine Recommendation RARE TUMOURS (Miscellaneous) Intracranial Meningioma Guidelines for the Management of Intracranial Meningioma Melanotic Neuroectodermal Tumour of Infancy Guidelines for the Management of Melanotic Neuroectodermal Tumour of Infancy Nasopharyngeal Carcinoma Guidelines for the Investigation and Management of Nasopharyngeal Carcinoma Adrenocortical Tumours (ACT)& Adrenocortical Guidelines on the Management of Adrenocortical Tumours ACT and Mitotane Carcinoma (ACC) Adrenocortical Carcinoma ACT Pancreatic Tumours Guidelines for the Investigation and Management of Pancreatic Tumours Endocrine Tumours - Craniopharyngioma / Adreno-cortical Tumours / Differentiated Thyroid Carcinoma / Phaeochromocytoma / MTC / Hyperparathyroidism & Pituitary Tumours (MEN) Guidelines - Paediatric Endocrine Tumour Guidelines GCSF administration Guidelines Kaposiform Haemangioendothelioma & Kasabach Sirolimus Sirolimus Merritt Syndrome RENAL Wilms Tumour SIOP Wilms UK Protocol SIOP - Follow Closed Trial Relapsed / Refractory Wilms and Clear Cell Sarcoma of Kidney RETIBLASTOMA Intraoccular Retinoblastoma I Chemotherapy Unilateral Retinoblastoma following primary enucleation Relapsed Retinoblastoma SOFT TISSUE SARCOMA Metastatic Rhabdomyosarcoma n-rhabdomyosarcoma Soft Tissue Sarcoma / Malignant Rhabdoid Tumour Relapsed Refractory Wilms Tumour and CCSK UKW-R Protocol - Follow Closed Trial Guidelines for the Management of Children with Intraocular Retinoblastoma I Chemotherapy Guidelines for the Management of Children with Advanced unilateral Retinoblastoma following primary enucleation Guidelines for the Management of Children with Intraocular Retinoblastoma II Second Line Chemotherapy Metastatic Rhabdomyosarcoma (RMS) Treatment Recommendations. Information in RMS A protocol for n Metastatic Rhabdomyosarcoma. Phase III. Closed Trial EpSSG NRSTS 2005 A protocol for n-rhabdomyosarcoma Soft Tissue Sarcomas. Closed trial (2008) Cyclophosphamide G-CSF EpSSG International Data Centre G-CSF EpSSG International Data Centre

7 n Metastatic Rhabdomyosarcoma Relapsed Rhabdomyosarcoma RELAPSED and REFRACTORY TUMOURS RMS 2005 STS A protocol for n Metastatic Rhabdomyosarcoma. Cyclophosphamide G-CSF EpSSG International Data Centre Closed trial follow standard arm Chemotherapy recommendations for relapsed RMS EpSSG Phase II committee Generic palliative chemotherapy solids and brain oral etoposide Etoposide tumours Relapsed and Refractory Extra Cranial Solid Gemcitabine and docetaxel no Tumours Relapsed and Refractory Extra Cranial Solid temozolomide and irinotecan +/- Vincristine (VIT) Temozolomide no Tumours and CNS Tumours STEM CELL TRANSPLANT EpSSG Phase II committee Published Protocol

Open / Closed to Recruitment. POSCU Involvement. Diagnosis Trial Oral Chemo Protocol Title Bone

Open / Closed to Recruitment. POSCU Involvement. Diagnosis Trial Oral Chemo Protocol Title Bone This list covers the Principal Treatment Centre (Alder Hey) and POSCUs including community services. It covers solid tumour oncology and haemato oncology clinical management protocols and agreed chemotherapy